Resmed (RMD) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Resmed (RMD) do?
Resmed Inc (RMD) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Manufactures continuous positive airway pressure machines, respiratory masks, and digital sleep monitoring systems. Connects millions of sleep apnea devices to proprietary cloud monitoring software for automated replacement supply. It is worth $33.32B on the market and sold $5.73B over the last year.
- Market cap
- $33.32B
- P/E ratio
- 21.6×
- Annual sales
- $5.73B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 12, 2026
Brands and businesses behind RMD
- AirSense: CPAP device line selling bedside sleep therapy machines with built-in cellular connectivity to clinics and distributors.
- AirFit: CPAP mask family generating recurring revenue through prescribed periodic silicone cushion and frame replacements.
- AirTouch: Memory foam CPAP mask line generating recurring sales through monthly disposable cushion replacements.
- AirView: Cloud-based clinical management system earning recurring service fees from healthcare providers monitoring therapy data.
- myAir: Patient engagement application and web portal that tracks sleep scores to encourage long-term equipment use.
RMD’s flags, in plain English
Each flag is a number from Resmed’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Low debt
Low debt, only 10% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Stupid Cash
Can pay this year's bills 2.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Fat Margins
Profit margin of 27.8%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Worth a Look
Expanding public use of GLP-1 weight loss medications creates competitive uncertainty around long-term sleep apnea hardware demand. Something here could change the picture, so it is worth reading next to the good news.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about RMD
How big is Resmed?
Resmed’s market cap is $33.32B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $5.73B: what customers paid the company over the last year, before any costs.
What is RMD’s P/E ratio?
RMD’s P/E ratio is 21.6×. Investors pay about 21.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with RMD?
The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Resmed’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RMD’s filings on SEC.gov. The Margin Monkey is research, not advice.
